Cardiovascular Monitoring of Children and Adolescents Receiving Psychotropic Drugs
1999; Lippincott Williams & Wilkins; Volume: 99; Issue: 7 Linguagem: Inglês
10.1161/01.cir.99.7.979
ISSN1524-4539
AutoresHoward P. Gutgesell, Dianne L. Atkins, Robyn J. Barst, Marcia L. Buck, Wayne Franklin, Richard A. Humes, Richard Ringel, Robert E. Shaddy, Kathryn A. Taubert,
Tópico(s)Pharmaceutical studies and practices
ResumoHomeCirculationVol. 99, No. 7Cardiovascular Monitoring of Children and Adolescents Receiving Psychotropic Drugs Free AccessOtherPDF/EPUBAboutView PDFView EPUBSections ToolsAdd to favoritesDownload citationsTrack citationsPermissions ShareShare onFacebookTwitterLinked InMendeleyRedditDiggEmail Jump toFree AccessOtherPDF/EPUBCardiovascular Monitoring of Children and Adolescents Receiving Psychotropic Drugs A Statement for Healthcare Professionals From the Committee on Congenital Cardiac Defects, Council on Cardiovascular Disease in the Young, American Heart Association Howard Gutgesell, Dianne Atkins, Robyn Barst, Marcia Buck, Wayne Franklin, Richard Humes, Richard Ringel, Robert Shaddy, , Kathryn A. Taubert and Howard GutgesellHoward Gutgesell , Dianne AtkinsDianne Atkins , Robyn BarstRobyn Barst , Marcia BuckMarcia Buck , Wayne FranklinWayne Franklin , Richard HumesRichard Humes , Richard RingelRichard Ringel , Robert ShaddyRobert Shaddy , , Kathryn A. TaubertKathryn A. Taubert and and membersand AHA Staff Originally published23 Feb 1999https://doi.org/10.1161/01.CIR.99.7.979Circulation. 1999;99:979–982OverviewReports of sudden deaths of children and adolescents treated with psychotropic medications have raised concerns regarding the appropriateness of this therapy, as well as the advisability of baseline and periodic electrocardiographic (ECG) monitoring of such patients.1234 What follows is a review of the drug effects on the ECG, cardiovascular effects of the commonly used psychotropic medications in children and adolescents, a summary of potentially dangerous drug interactions, and recommendations for cardiovascular monitoring.Potential Mechanisms for Sudden DeathAlthough medications can potentially cause sudden, unexpected death by a variety of mechanisms (eg, seizures, central nervous system depression, or coronary artery spasm), cardiac arrhythmias are the most frequent cause. In particular, a unique form of ventricular tachycardia termed torsade de pointes has been recognized as the arrhythmia responsible for the so-called proarrhythmic effect of several antiarrhythmia drugs, and recent evidence has pointed to a similar mechanism in syncope and deaths related to other medications5 and in the familial long-QT syndromes.6 The common feature of these conditions is delayed repolarization of the myocardium (related to abnormal sodium or potassium currents) with resultant prolongation of the QT interval of the ECG. This appears to leave the myocardium vulnerable to ventricular tachycardia, primarily in the setting of bradycardia but occasionally in association with exercise.Other ECG abnormalities, such as sinus node depression, second- or third-degree heart block, and supraventricular tachycardia, seem unlikely causes of sudden death in patients receiving psychotropic medications. Additionally, the rSR′ pattern in lead V1, sometimes referred to as incomplete right bundle-branch block or right ventricular conduction delay, is a normal childhood variant and is not a risk factor for sudden death.Specific DrugsThe major cardiovascular and electrophysiological effects of the commonly used psychotropic drugs are listed in Table 1. Stimulants such as the amphetamines and methylphenidate (Ritalin) cause slight but clinically insignificant increases in heart rate and blood pressure. The tricyclic antidepressants (TCA) imipramine and desipramine have been associated with at least 7 reported deaths in young patients.17 The precise mechanism of death has not been documented. Some of the patients have had toxic levels of drugs, and at least 2 had risk factors for sudden death (a coronary anomaly in 1 and a family history of sudden death in another). The ECG effects of TCA administration include an increase in heart rate (by 20% to 25%), prolongation of the PR interval (by 5% to 10%), increase in QRS duration (by 7% to 25%), and prolongation of the QT interval (by 3% to 10%). Although 8% of patients have a corrected QT interval (QTc) of >460 ms, the mean value of the QTc remained within normal limits for pediatric patients.4891011 Malignant arrhythmias, in particular torsade de pointes, have not been documented except for the ventricular fibrillation observed in the emergency room in the patient with a family history of sudden death.The selective serotonin reuptake inhibitors have minimal cardiovascular effects; deaths have been rare, even with massive overdose. Clonidine, a widely used antihypertensive medication, has been associated with 2 deaths in patients who also received methylphenidate, but the mechanism for these deaths is unknown and may have been sudden cessation of treatment.Drug InteractionsMany psychotropic medications are metabolized by the cytochrome P450 system, an enzyme system that may be inhibited by a multitude of medications12 (Table 2). Adverse effects have occurred when the P450 system is inhibited, which leads to elevated levels of medications that prolong the QT interval and produce ventricular tachycardia (torsade de pointes). Most notable have been deaths related to torsade de pointes from nonsedating histamine-blocking agents such as terfenadine (Seldane) and astemizole (Hismanal).13 Many of these episodes were associated with coadministration of other medications such as macrolide antibiotics or imidazole antifungal agents (Table 2). Other classes of medications that inhibit or are metabolized by the P450 cytochrome system include antidepressants, calcium channel blockers, histamine blockers, gastrointestinal motility agents, and steroids. Prolongation of the QT interval and torsade de pointes have been reported in young children taking cisapride.Antiarrhythmic drugs of class Ia (eg, disopyramide, procainamide, and quinidine) and class III (eg, amiodarone and sotalol) likewise prolong the QT interval, and therefore concomitant use of psychotropic medications with these drugs is not recommended.Family HistoryIn some families, syncope and sudden death have been related to familial prolongation of the QT interval and torsade de pointes. Such individuals are at increased risk for arrhythmias due to medications that prolong the QT interval. Drugs that prolong the QT interval are contraindicated in patients with familial long-QT syndrome.RecommendationsBefore therapy with psychotherapeutic agents is initiated, a careful history should be obtained, with special attention to symptoms such as palpitations, syncope, or near syncope. Medication use (prescribed and over-the-counter) should be determined. The family history should be reviewed with reference to the long-QT syndrome or other causes of sudden, unexplained death. Detection of these symptoms or risk factors warrants a cardiovascular evaluation by a pediatric cardiologist before initiation of therapy.At follow-up visits, patients receiving psychotropic drug therapy should be questioned about the addition of any drugs and the occurrence of any of the above symptoms. The physical examination should include determination of heart rate and blood pressure.Despite the lack of understanding of the mechanism of sudden death in young patients taking TCAs or demonstration that ECG monitoring could prevent these deaths, ECG monitoring at baseline and during chronic therapy has been recommended.41415 Until more data are available, it seems prudent to obtain an ECG at baseline before TCA or phenothiazine therapy is begun (primarily to detect unsuspected instances of long-QT syndrome) and another when steady state is achieved. If the sustained resting heart rate is >130 bpm, the PR interval is >200 ms, QRS is >120 ms, or QTc is >460 ms, or if symptoms such as palpitations, near syncope, or syncope develop, alternative therapy may need to be considered along with pediatric cardiology consultation.Concomitant use of psychotropic drugs and other drugs that are metabolized by or inhibit the P450 enzyme system should be avoided.This statement was approved by the American Heart Association Science Advisory and Coordinating Committee in November 1998. A single reprint is available by calling 800-242-8721 (US only) or writing the American Heart Association, Public Information, 7272 Greenville Avenue, Dallas, TX 75231-4596. Ask for reprint No. 71-0159. To purchase additional reprints: up to 999 copies, call 800-611-6083 (US only) or fax 413-665-2671; 1000 or more copies, call 214-706-1466, fax 214-691-6342, or Table 1. Cardiac Effects of Psychotropic MedicationsClassMedicationCardiac Effects and CommentsRecommendations for Cardiovascular MonitoringStimulantsMethylphenidate (Ritalin)Cardiovascular • Mild tachycardia and increase in blood pressure • Adrenergic blockers are inhibited • Sympathomimetics are enhanced • Report of sudden death in 1 child treated simultaneously with clonidineNo specific cardiovascular monitoring is indicatedPemoline (Cylert)• Minimal cardiac effects • HepatotoxicityNo specific cardiovascular monitoring is indicatedDextroamphetamine• Tachycardia/palpitationsNo specific cardiovascular monitoring is indicatedAntidepressantsTCAsDesipramine (Norpramin); imipramineCardiovascular • Rare reports of sudden death • Prolongation of the QTc, PR, QRS • Sinus tachycardia Other • Cimetidine increases levels of TCA • Ritalin decreases the metabolism • May increase action of other sympathomimetic agents • Watch drug-drug interactions!1. Baseline history and physical 2. Current medication history 3. Baseline ECG measuring: • PR ≤200 ms • QRS duration ≤120 ms • QTc ≤460 ms 4. Follow-up ECG and history after a steady state is achieved on 3–5 mg/kg for desipramine and 3–5 mg/kg for imipramineSelective serotonin reuptake inhibitorsFluoxetine (Prozac)Cardiovascular • No significant ECG change • Interacts with protein-bound medications such as digoxin and warfarinNo specific cardiovascular monitoring is indicated Digoxin and warfarin dose may need adjustmentSertraline (Zoloft)Cardiovascular • No significant ECG abnormalities • Mild tachycardia Other • No MAOIParoxetine (Paxil)No significant cardiac effects P450: evaluate other medicationsPossible interaction with P450 systemOther antidepressantsBupropion (Wellbutrin)Little information on cardiac effects Dopamine agonistNo specific cardiovascular monitoring is indicatedLithiumCardiovascular • Reports of arrhythmias • Flattened T waves Other • Monitor levels • Diuretics decrease renal clearance (especially thiazide diuretics)No specific cardiovascular monitoring is indicatedOther psychotropic agentsα-2 Adrenergic agonistClonidine (Catapres)Cardiovascular • Hypotension • Rebound hypertension when discontinuing1. Monitor blood pressure when medication is started 2. Monitor blood pressure when weaning from the medication 3. No ECG monitoring is necessaryGuanfacine (Tenex)• Similar to clonidineAntipsychotics/neurolepticsPhenothiazinesChlorpromazine Thioridazine Mesoridazine Perphenazine Trifluoperazine FluphenazineCardiovascular • Tachycardia (anticholinergic) • Hypotension • Prolongation of the QTc (be aware of other medications that prolong the QTc)1. Baseline history and physical 2. Current medication history 3. Baseline ECG measuring: • PR ≤200 ms • QRS duration ≤120 ms • QTc ≤460 ms 4. Follow-up ECG and history after therapeutic levels are reachedButyrophenonesHaloperidol (Haldol)Cardiovascular • Tachycardia (anticholinergic) • Hypotension • Prolongation of the QTc (be aware of other medications that prolong the QTc)1. Baseline history and physical 2. Current medication history 3. Baseline ECG measuring: • PR ≤200 ms • QRS duration ≤120 ms • QTc ≤460 ms 4. Follow-up ECG and history after therapeutic levels are reachedDiphenylbutylpiperidinePimozide (Orap)Cardiovascular • Prolongation of QTc (be aware of other medications that prolong the QTc)1. Baseline history and physical 2. Current medication history 3. Baseline ECG measuring: • PR ≤200 ms • QRS duration ≤120 ms • QTc ≤460 ms 4. Follow-up ECG and history after therapeutic levels are reachedDihydroindoloneMolindone (Moban)Sinus tachycardia One of the few tranquilizers without a warning about the QTcNo specific cardiovascular monitoring is indicatedMAOI indicates monoamine oxidase inhibitor. Table 2. Potential Drug InteractionsGroup A. Drugs metabolized by the cytochrome P450 enzyme systems11. PsychotropicsAmitriptylineClomipramineDesipramineImipramineNortriptylineThioridazine2. AntiepilepticsCarbamazepinePhenytoinValproic acid3. AntiarrhythmicsAmiodaroneDiltiazemEncainideFelodipineFlecainideMetoprololNifedipinePropranololQuinidineTimololVerapamil4. OtherCisaprideCyclosporineLovastatinOmeprazoleTacrolimusTerfenadineWarfarinGroup B. Drugs inhibiting the cytochrome P450 enzyme systems11. AntibioticsClarithromycinErythromycinFluconazoleItraconazoleKetoconazoleMiconazole2. PsychotropicsFluoxetineFluvoxamineHaloperidolParoxetine3. OtherCimetidineGrapefruit juiceQuinidine1Concomitant use of drugs from group A and group B may result in augmentation of pharmacological and toxic effects of group A drugs. Drug reduction and careful monitoring is required. References 1 Popper CW, Zimnitzky B. Sudden death putatively related to desipramine treatment in youth: a fifth case and a review of speculative mechanisms. J Child Adolesc Psychopharmacol.1995; 5:283–300.CrossrefGoogle Scholar2 Werry JS, Biederman J, Thisted R, Greenhill L, Ryan N. Resolved: cardiac arrhythmias make desipramine an unacceptable choice in children. J Am Acad Child Adolesc Psychiatry.1995; 34:1239–1245; discussion 1245–1248.CrossrefMedlineGoogle Scholar3 Biederman J, Thisted RA, Greenhill LL, Ryan ND. Estimation of the association between desipramine and the risk for sudden death in 5- to 14-year-old children. J Clin Psychiatry.1995; 56:87–93.MedlineGoogle Scholar4 Biederman J, Baldessarini RJ, Wright V, Knee D, Harmatz JS, Goldblatt A. A double-blind placebo controlled study of desipramine in the treatment of ADD, II: serum drug levels and cardiovascular findings. J Am Acad Child Adolesc Psychiatry.1989; 28:903–911.CrossrefMedlineGoogle Scholar5 Roden DM, Thompson KA, Hoffman BF, Woosley RL. Clinical features and basic mechanisms of quinidine-induced arrhythmias. J Am Coll Cardiol. 1986;8(suppl A):73A–78A.Google Scholar6 Keating MT, Sanguinetti MC. Molecular genetic insights into cardiovascular disease. Science.1996; 272:681–685. Review.CrossrefMedlineGoogle Scholar7 Riddle MA, Nelson JC, Kleinman CS, Rasmusson A, Leckman JF, King RA, Cohen DJ. Sudden death in children receiving Norpramin: a review of three reported cases and commentary. J Am Acad Child Adolesc Psychiatry.1991; 30:104–108.CrossrefMedlineGoogle Scholar8 Schroeder JS, Mullin AV, Elliott GR, Steiner H, Nichols M, Gordon A, Paulos M. Cardiovascular effects of desipramine in children [see comments in J Am Acad Child Adolesc Psychiatry.1989; 28:964–965]. J Am Acad Child Adolesc Psychiatry. 1989;28:376–379.CrossrefMedlineGoogle Scholar9 Wilens TE, Biederman J, Baldessarini RJ, Geller B, Schleifer D, Spencer TJ, Birmaher B, Goldblatt A. Cardiovascular effects of therapeutic doses of tricyclic antidepressants in children and adolescents. J Am Acad Child Adolesc Psychiatry.1996; 35:1491–1501. Review.CrossrefMedlineGoogle Scholar10 Wilens TE, Biederman J, Baldessarini RJ, Puopolo PR, Flood JG. Electrocardiographic effects of desipramine and 2-hydroxydesipramine in children, adolescents, and adults treated with desipramine. J Am Acad Child Adolesc Psychiatry.1993; 32:798–804.CrossrefMedlineGoogle Scholar11 Fletcher SE, Case CL, Sallee FR, Hand LD, Gillette PC. Prospective study of the electrocardiographic effects of imipramine in children. J Pediatr.1993; 122:652–654.CrossrefMedlineGoogle Scholar12 Slaughter RL, Edwards DJ. Recent advances: the cytochrome P450 enzymes. Ann Pharmacother.1995; 29:619–624.CrossrefMedlineGoogle Scholar13 Woosley RL, Chen Y, Freiman JP, Gillis RA. Mechanism of the cardiotoxic actions of terfenadine [see comments in JAMA.1993; 269:1550–1552]. JAMA. 1993;269:1532–1536.CrossrefMedlineGoogle Scholar14 Wagner KD, Fershtman M. Potential mechanism of desipramine-related sudden death in children. Psychosomatics.1993; 34:80–83.CrossrefMedlineGoogle Scholar15 Elliott GR, Popper CW. Tricyclic antidepressants: the QT interval and other cardiovascular parameters. J Child Adolesc Psychopharmacol.1990; 1:187–189.CrossrefGoogle Scholar Previous Back to top Next FiguresReferencesRelatedDetailsCited By Das B, Rawat V, Ramasubbu S, Agnihotri A and Kumar B (2022) Potential drug-drug interaction prevalence and risk factors associated with QT interval prolonging psychotropic use in children and adolescents, Progress in Pediatric Cardiology, 10.1016/j.ppedcard.2021.101456, 64, (101456), Online publication date: 1-Mar-2022. Pesce M, Puoti M, Rybak A, Andreozzi M, Bruzzese E, Sarnelli G and Borrelli O (2021) Pharmacological interventions for pediatric irritable bowel syndrome, Expert Opinion on Pharmacotherapy, 10.1080/14656566.2021.1976753, 23:1, (91-103), Online publication date: 2-Jan-2022. Becker S, Rochelson E, Lienhard M, Silber D, Mowrey W and Hutchison L (2020) Screening Electrocardiograms Have Low Utility in Medical Clearance Before Pediatric Inpatient Psychiatric Admission, Pediatric Emergency Care, 10.1097/PEC.0000000000002298, 38:1, (e393-e397), Online publication date: 1-Jan-2022. Cassidy A, Ilardi D, Bowen S, Hampton L, Heinrich K, Loman M, Sanz J and Wolfe K (2017) Congenital heart disease: A primer for the pediatric neuropsychologist, Child Neuropsychology, 10.1080/09297049.2017.1373758, 24:7, (859-902), Online publication date: 3-Oct-2018. Rozel J, Stowell K and Thorkelson G (2017) Diagnosis and Management of Agitation in Children and Adolescents The Diagnosis and Management of Agitation, 10.1017/9781316556702.020, (253-270) Aggarwal V, Aggarwal A and Khan D (2015) Electrocardiogram before starting stimulant medications: to order or not?, Cardiology in the Young, 10.1017/S1047951115001274, 26:1, (216-219), Online publication date: 1-Jan-2016. Antel J, Albayrak Ö, Heusch G, Banaschewski T and Hebebrand J (2014) Assessment of potential cardiovascular risks of methylphenidate in comparison with sibutramine: do we need a SCOUT (trial)?, European Archives of Psychiatry and Clinical Neuroscience, 10.1007/s00406-014-0522-8, 265:3, (233-247), Online publication date: 1-Apr-2015. Bell G and Efron D (2015) Tricyclic antidepressants - third-line treatment for attention deficit hyperactivity disorder in school-aged children, Journal of Paediatrics and Child Health, 10.1111/jpc.13031, 51:12, (1232-1234), Online publication date: 1-Dec-2015. Prince J, Morrison N and Wilens T (2014) Pharmacotherapy of ADHD in adults Attention-Deficit Hyperactivity Disorder in Adults and Children, 10.1017/CBO9781139035491.023, (276-297) Mathew E, Kim E and Goldschneider K (2014) Pharmacological Treatment of Chronic Non-Cancer Pain in Pediatric Patients, Pediatric Drugs, 10.1007/s40272-014-0092-2, 16:6, (457-471), Online publication date: 1-Dec-2014. Chau P and Moore J (2013) Psychiatric Disorder and Incessant Tachyarrhythmia in a Child, Case Reports in Pediatrics, 10.1155/2013/572301, 2013, (1-4), . Hajishengallis E (2013) Psychotropic drugs and their impact on the treatment of paediatric dental patients, European Archives of Paediatric Dentistry, 10.1007/s40368-013-0053-4, 14:4, (197-206), Online publication date: 1-Aug-2013. Heleniak C, Kaur T, Ghalib K and Rynn M (2012) Tricyclic Antidepressants and Monoamine Oxidase Inhibitors for the Treatment of Child and Adolescent Psychiatric Disorders Pharmacotherapy of Child and Adolescent Psychiatric Disorders, 10.1002/9781119958338.ch7, (105-129), Online publication date: 13-Jan-2012. Hamilton R, Rosenthal E, Hulpke-Wette M, Graham J and Sergeant J (2011) Cardiovascular considerations of attention deficit hyperactivity disorder medications: a report of the European Network on Hyperactivity Disorders work group, European Attention Deficit Hyperactivity Disorder Guidelines Group on attention deficit hyperactivity disorder drug safety meeting, Cardiology in the Young, 10.1017/S1047951111000928, 22:1, (63-70), Online publication date: 1-Feb-2012. Batra A, Alexander M and Silka M (2012) Attention-Deficit/Hyperactivity Disorder, Stimulant Therapy, and the Patient with Congenital Heart Disease: Evidence and Reason, Pediatric Cardiology, 10.1007/s00246-012-0162-6, 33:3, (394-401), Online publication date: 1-Mar-2012. Gutgesell H (2011) Screening for Cardiovascular Disease in the Young, Congenital Heart Disease, 10.1111/j.1747-0803.2011.00501.x, 6:2, (88-97), Online publication date: 1-Mar-2011. Chiou E and Nurko S (2011) Functional abdominal pain and irritable bowel syndrome in children and adolescents, Therapy, 10.2217/thy.11.7, 8:3, (315-331), Online publication date: 1-May-2011. (2011) Medications Affecting Behavior and Learning Learning and Attention Disorders in Adolescence and Adulthood, 10.1002/9781118093085.ch18, (489-535) Welniarz B and Lauth B (2011) Le traitement de l'hyperactivité, Perspectives Psy, 10.1051/ppsy/2011501078, 50:1, (78-85), Online publication date: 1-Jan-2011. Plattner A and Dantz B (2011) Tricyclic Antidepressants, Psychopharm Review, 10.1097/01.IDT.0000394069.44268.50, 46:3, (17-23), Online publication date: 1-Mar-2011. Wilens T, Morrison N and Prince J (2014) An update on the pharmacotherapy of attention-deficit/hyperactivity disorder in adults, Expert Review of Neurotherapeutics, 10.1586/ern.11.137, 11:10, (1443-1465), Online publication date: 1-Oct-2011. Plattner A and Dantz B (2011) The Tricyclics: More than Just Antidepressants, Psychiatric Annals, 10.3928/00485713-20110224-05, 41:3, (158-165), Online publication date: 1-Mar-2011. Sonnier L and Barzman D (2011) Pharmacologic Management of Acutely Agitated Pediatric Patients, Pediatric Drugs, 10.2165/11538550-000000000-00000, 13:1, (1-10), Online publication date: 1-Feb-2011. Kireyev D, Arkhipov M, Zador S, Paris J and Boden W (2010) Clinical Utility of aVR-The Neglected Electrocardiographic Lead, Annals of Noninvasive Electrocardiology, 10.1111/j.1542-474X.2010.00359.x, 15:2, (175-180), Online publication date: 1-Apr-2010. Wilens T and Spencer T (2015) Understanding Attention-Deficit/Hyperactivity Disorder from Childhood to Adulthood, Postgraduate Medicine, 10.3810/pgm.2010.09.2206, 122:5, (97-109), Online publication date: 1-Sep-2010. Prince J and Wilens T (2010) TRATAMIENTO FARMACOLÓGICO DEL TDAH Y LAS COMORBILIDADES Comorbilidades del TDAH, 10.1016/B978-84-458-2021-6.00019-1, (339-384), . Lorberg B and Prince J (2010) Psychopharmacological Management of Children and Adolescents Massachusetts General Hospital Handbook of General Hospital Psychiatry, 10.1016/B978-1-4377-1927-7.00035-2, (467-498), . Chiou E and Nurko S (2014) Management of functional abdominal pain and irritable bowel syndrome in children and adolescents, Expert Review of Gastroenterology & Hepatology, 10.1586/egh.10.28, 4:3, (293-304), Online publication date: 1-Jun-2010. Thompson J and Thompson J (2010) Acute Myocardial Infarction Related to Methylphenidate for Adult Attention Deficit Disorder, The Journal of Emergency Medicine, 10.1016/j.jemermed.2007.06.021, 38:1, (18-21), Online publication date: 1-Jan-2010. Hammerness P, Wilens T, Mick E, Spencer T, Doyle R, McCreary M, Becker J and Biederman J (2009) Cardiovascular Effects of Longer-Term, High-Dose OROS Methylphenidate in Adolescents with Attention Deficit Hyperactivity Disorder, The Journal of Pediatrics, 10.1016/j.jpeds.2009.02.008, 155:1, (84-89.e1), Online publication date: 1-Jul-2009. Eisenberg L and Belfer M (2009) Prerequisites for global child and adolescent mental health, Journal of Child Psychology and Psychiatry, 10.1111/j.1469-7610.2008.01984.x, 50:1-2, (26-35), Online publication date: 1-Jan-2009. Lin Y, Wu Y and Tsai G (2009) Electrocardiographic monitoring for QT prolongation in patients treated with ziprasidone-A claims database approach, Pharmacoepidemiology and Drug Safety, 10.1002/pds.1791, 18:9, (842-847), Online publication date: 1-Sep-2009. Newcorn J and Donnelly C (2009) Cardiovascular safety of medication treatments for attention-deficit/hyperactivity disorder, Mount Sinai Journal of Medicine: A Journal of Translational and Personalized Medicine, 10.1002/msj.20096, 76:2, (198-203), Online publication date: 1-Apr-2009. Hammerness P, Wilens T, Berul C and Elkort M (2008) SUPRAVENTRICULAR TACHYCARDIA IN AN ADOLESCENT WITH ATTENTION-DEFICIT/HYPERACTIVITY DISORDER (ADHD), Journal of the American Academy of Child & Adolescent Psychiatry, 10.1097/chi.0b013e31815d7485, 47:2, (219-220), Online publication date: 1-Feb-2008. Prince J, Spencer T, Wilens T and Biederman J (2008) Pharmacotherapy of Attention-Deficit/Hyperactivity Disorder across the Life Span Massachusetts General Hospital Comprehensive Clinical Psychiatry, 10.1016/B978-0-323-04743-2.50051-2, (667-685), . Li B, Lefevre F, Chelimsky G, Boles R, Nelson S, Lewis D, Linder S, Issenman R and Rudolph C (2008) North American Society for Pediatric Gastroenterology, Hepatology, and Nutrition Consensus Statement on the Diagnosis and Management of Cyclic Vomiting Syndrome, Journal of Pediatric Gastroenterology & Nutrition, 10.1097/MPG.0b013e318173ed39, 47:3, (379-393), Online publication date: 1-Sep-2008. Towbin K (2008) Paying Attention to Stimulants: Height, Weight, and Cardiovascular Monitoring in Clinical Practice, Journal of the American Academy of Child & Adolescent Psychiatry, 10.1097/CHI.0b013e31817e0eb9, 47:9, (977-980), Online publication date: 1-Sep-2008. McGregor A (2008) A Case That Is Not for the Faint of Heart, Seminars in Pediatric Neurology, 10.1016/j.spen.2008.10.003, 15:4, (167-172), Online publication date: 1-Dec-2008. Mong S, Pomeroy S, Cecchin F, Juraszek A and Alexander M (2008) Cardiac Risk After Craniopharyngioma Therapy, Pediatric Neurology, 10.1016/j.pediatrneurol.2007.11.007, 38:4, (256-260), Online publication date: 1-Apr-2008. Newcorn J (2014) Cardiovascular Safety of ADHD Medication Treatments, CNS Spectrums, 10.1017/S1092852900003254, 13:S15, (5-8), Online publication date: 1-Oct-2008. (2008) References Brain‐Based Therapy with Children and Adolescents, 10.1002/9781118265666.refs, (230-279), Online publication date: 3-Nov-2008. Rostain A (2015) Attention-Deficit/Hyperactivity Disorder in Adults: Evidence-Based Recommendations for Management, Postgraduate Medicine, 10.3810/pgm.2008.09.1905, 120:3, (27-38), Online publication date: 1-Jan-2008. &NA; (2007) The pharmacological treatment of attention-deficit hyperactivity disorder (ADHD) in adolescents is effective and relatively safe, Drugs & Therapy Perspectives, 10.2165/00042310-200723110-00003, 23:11, (9-12), Online publication date: 1-Nov-2007. McNally P, McNicholas F and Oslizlok P (2006) The QT interval and psychotropic medications in children, European Child & Adolescent Psychiatry, 10.1007/s00787-006-0573-0, 16:1, (33-47), Online publication date: 1-Feb-2007. Hazell P (2007) Pharmacological Management of Attention-Deficit Hyperactivity Disorder in Adolescents, CNS Drugs, 10.2165/00023210-200721010-00004, 21:1, (37-46), . Newcorn J (2014) Age-Related Considerations in the Treatment of ADHD, CNS Spectrums, 10.1017/S1092852900003795, 12:S23, (10-13), Online publication date: 1-Dec-2007. Posey D and McDougle C (2007) Guanfacine and Guanfacine Extended Release: Treatment for ADHD and Related Disorders, CNS Drug Reviews, 10.1111/j.1527-3458.2007.00026.x, 13:4, (465-474) Wilens T, Biederman J, Spencer T and Prince J (2007) Stimulants and Sudden Death: What Is the Real Risk?: In Reply, Pediatrics, 10.1542/peds.2006-3213, 119:2, (409-410), Online publication date: 1-Feb-2007. KRULEWICZ S, CARPENTER D, FONG R, HORRIGAN J, LIPSCHITZ A, PERERA P and WAGNER K (2006) Analysis of Electrocardiographic Data Following Use of Paroxetine in Pediatric Depression and Obsessive-Compulsive Disorder, Journal of the American Academy of Child & Adolescent Psychiatry, 10.1097/01.chi.0000198593.30702.48, 45:4, (422-430), Online publication date: 1-Apr-2006. Scahill L, Erenberg G, Berlin C, Budman C, Coffey B, Jankovic J, Kiessling L, King R, Kurlan R, Lang A, Mink J, Murphy T, Zinner S and Walkup J (2006) Contemporary assessment and pharmacotherapy of Tourette syndrome, NeuroRX, 10.1016/j.nurx.2006.01.009, 3:2, (192-206), Online publication date: 1-Apr-2006. Wilens T, Prince J, Spencer T and Biederman J (2006) Stimulants and Sudden Death: What Is a Physician to Do?, Pediatrics, 10.1542/peds.2006-0942, 118:3, (1215-1219), Online publication date: 1-Sep-2006. Friday R, Ross P and McDaniel N (2005) Congenital Heart Disease ECG in Emergency Medicine and Acute Care, 10.1016/B978-0-323-01811-1.50058-4, (238-252), . Connor D and Spencer T (2014) Short-Term Cardiovascular Effects of Mixed Amphetamine Salts Extended Release in Children and Adolescents With Oppositional Defiant Disorder, CNS Spectrums, 10.1017/S1092852900014127, 10:S15, (31-38), Online publication date: 1-Oct-2005. Welniarz B (2004) Le traitement de l'hyperactivité : autour de la prescription de psychostimulants, Perspectives Psy, 10.1051/ppsy/2004431065, 43:1, (65-71), Online publication date: 1-Jan-2004. Niederhofer H, Staffen W and Mair A (2016) A placebo-controlled study of lofexidine in the treatment of children with tic disorders and attention deficit hyperactivity disorder, Journal of Psychopharmacology, 10.1177/0269881103017001714, 17:1, (113-119), Online publication date: 1-Jan-2003. Heyneman E (2003) The aggressive child, Child and Adolescent Psychiatric Clinics of North America, 10.1016/S1056-4993(03)00040-3, 12:4, (667-677), Online publication date: 1-Oct-2003. Sugiyama A, Satoh Y, Shiina H, Takeda S and Hashimoto K (2002) Torsadegenic Action of the Antipsychotic Drug Sulpiride Assessed Using In Vivo Canine Models, Journal of Cardiovascular Pharmacology, 10.1097/00005344-200208000-00009, 40:2, (235-245), Online publication date: 1-Aug-2002. Kunkler K (2002) Acquired Long QT Syndrome: Risk Assessment, Prudent Prescribing and Monitoring, and Patient Education, Journal of the American Academy of Nurse Practitioners, 10.1111/j.1745-7599.2002.tb00139.x, 14:9, (382-389), Online publication date: 1-Sep-2002. Masters K and Bellonci C (2002) Practice Parameter for the Prevention and Management of Aggressive Behavior in Child and Adolescent Psychiatric Institutions, With Special Reference to Seclusion and Restraint, Journal of the American Academy of Child & Adolescent Psychiatry, 10.1097/00004583-200202001-00002, 41:2, (4S-25S), Online publication date: 1-Feb-2002. Francis P (2002) Effects of psychotropic medications on the pediatric electrocardiogram and recommendations for monitoring, Current Opinion in Pediatrics, 10.1097/00008480-200204000-00014, 14:2, (224-230), Online publication date: 1-Apr-2002. Cheng K and Myers K (2001) Pharmacological Interventions Advanced Abnormal Psychology, 10.1007/978-1-4419-8497-5_24, (507-539), . Sugiyama A, Satoh Y and Hashimoto K (2001) In Vivo Canine Model Comparison of Cardiohemodynamic and Electrophysiological Effects of a New Antipsychotic Drug Aripiprazole (OPC-14597) to Haloperidol, Toxicology and Applied Pharmacology, 10.1006/taap.2001.9168, 173:2, (120-128), Online publication date: 1-Jun-2001. White E (2000) Patients with Implantable Cardioverter Defibrillators: Transition to Home, The Journal of Cardiovascular Nursing, 10.1097/00005082-200004000-00007, 14:3, (42-52), Online publication date: 1-Apr-2000. Tamargo J (2000) Drug-Induced Torsade de Pointes: From Molecular Biology to Bedside, Japanese Journal of Pharmacology, 10.1016/S0021-5198(19)30621-3, 83:1, (1-19), . Satoh Y, Sugiyama A, Tamura K and Hashimoto K (2000) Effect of Magnesium Sulfate on the Haloperidol-Induced QT Prolongation Assessed in the Canine In Vivo Model Under the Monitoring of Monophasic Action Potential, Japanese Circulation Journal, 10.1253/jcj.64.445, 64:6, (445-451), . Ueda K and Black K (2021) A Comprehensive Review of Tic Disorders in Children, Journal of Clinical Medicine, 10.3390/jcm10112479, 10:11, (2479) February 23, 1999Vol 99, Issue 7Article InformationMetrics Copyright © 1999 by American Heart Associationhttps://doi.org/10.1161/01.CIR.99.7.979PMID: 10027824 Originally publishedFebruary 23, 1999 Keywordspsychotropic drugsdeath, suddenAHA Scientific StatementsPDF download Advertisement
Referência(s)